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Abstract
Background: Hyperhomocysteinemia and lipid abnormalities are commonly found in patients
with chronic renal failure; both are recognized as risk factors for atherosclerosis. The
homocysteine-lowering effect of pyridoxine is controversial. This study was performed to
determine the effect of a high dose of pyridoxine (300 mg i.v. three times a week) on plasma and
red blood cell lipid profile and plasma homocysteine concentration in twelve chronic renal failure
patients on regular hemodialysis. Fasting blood samples were taken at the beginning of the study
(basal 1), after 30 and 60 days of treatment and 4 months after withdrawal (basal 2).
Results: Pyridoxine supplementation induced a significant decrease in total plasma homocysteine
level and also a lowering effect in plasma total cholesterol and triglycerides. These biochemical data
increased when the samples were taken at basal 2, reaching the levels obtained at the beginning of
the experiment. LDL cholesterol increased whereas HDL cholesterol was reduced during the
treatment. In erythrocyte membranes vitamin B6 therapy enhanced the cholesterol/phospholipid
ratio as well as the fluorescence anisotropy of diphenyl-hexatriene.
Conclusions: We conclude that high doses of pyridoxine represent an effective strategy to
ameliorate both plasma homocysteine levels and lipid profiles in chronic renal failure patients,
protecting them from atherosclerosis. Further research using a long-term treatment would be
necessary in an attempt to restore the fatty acid pattern and the fluidity of red cell membranes.
Background
Ischemic heart disease and other complications of athero-
sclerosis are the most common cause of death in patients
with chronic renal failure. The pathogenesis of cardiovas-
cular diseases in these patients is of multifactorial origin
[1]. Dislipidemia and hyperhomocysteinemia are impor-
tant factors associated with the early onset of
atherosclerosis.
Chronic renal failure is often associated with dyslipopro-
teinemia, high levels of cholesterol and triglycerides, as
well as a decrease in the polyunsaturated fatty acids. Each
of these abnormalities has been identified as an
independent risk factor for atherosclerosis [2–5]. Some of
them persisting and becoming worse during dialysis treat-
ment [6]. On the other hand, an increment of plasma
homocysteine concentration is highly prevalent among
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independent risk factor for atherosclerotic complications
of end-stage renal disease [2,9–12].
Hiperhomocysteinemia is closely linked to plasma folate
and pyridoxine concentration [9]. Once formed, homo-
cysteine is either remethylated to methionine which
requires vitamin B12, folate and riboflavin as a cofactor,
cosubstrate, and prosthetic group, respectively, or it
undergoes a transsulfuration reaction to form cysteine.
The transsulfuration pathway is catalyzed by cystathio-
nine beta synthase which requires pyridoxine (vitamin
B6) as a cofactor. In patients with myocardial infarction,
Verhoef and col. [13] demonstrated that the impairment
of homocysteine remethylation (dependent on folate and
vitamin B12 rather than on vitamin B6) was the predom-
inant cause of high homocysteine levels. An increase in
the intermediate products of the transsulfuration pathway
was demonstrated in chronic renal disease, including end-
stages requiring hemodialysis [14]. In a large cohort of
unsupplemented hemodialysis patients it was shown that
hyperhomocysteinemia was present in all the patients,
though not all of them were deficient in B-complex vita-
mins [15]. Moreover, hyperhomocysteinemia persists in
75% of dialysis patients despite the routine low dose sup-
plementation with the B-vitamin cofactor/substrates for
homocysteine metabolism, and normal or supernormal
plasma status of these vitamins [16].
Much of the research on determinants of total homo-
cysteine concentration was focused on folate. It was
recently demonstrated that supplementation with high
doses of folic acid reduced plasma homocysteine levels in
chronic renal failure patients on regular hemodialysis
[17,18]. Nevertheless, this therapy induced significant
alterations in both plasma and erythrocyte membrane
lipid profile which should be taken into account when
this therapy is indicated [17].
To correct hyperhomocysteinemia in dialyzed patients
supra physiologic doses of B-vitamins [19], or pharmaco-
logic doses of folic acid and pyridoxine [20] were sug-
gested. The effect of vitamin B6 was missed in many trials
because of a much greater effect of folic acid. On the other
hand, it was previously observed that oral pyridoxine sup-
plementation had no significant effect on fasting total
homocysteine levels in nondialyzed chronic renal failure
patients [21] while a lowering effect appeared when it was
administered intravenously associated to folic acid [22].
In healthy subjects who are folate and riboflavin replete,
low-dose vitamin B6 lowers fasting plasma homocysteine
levels [23].
In the present study, we conducted a two-month trial in
chronic renal failure patients undergoing regular hemodi-
alysis in order to assess the effect of the intravenous sup-
plementation of high doses of pyridoxine on plasma
homocysteine levels as well as its incidence on the lipid
profile of plasma and erythrocytes.
Results
Table 1 shows the values for plasma total homocysteine,
triglycerides, total cholesterol as well as HDL-cholesterol
and LDL-cholesterol levels in the population studied, at
the beginning (basal 1), 30 and 60 days after pyridoxine
treatment, and four months after withdrawal of treatment
(basal 2). Data taken at the beginning of the study showed
levels of homocysteine higher than those considered as
normal [24]. Pyridoxine administration significantly
decreased plasma total homocysteine concentration to
normal values, which became high again once the medi-
cation was suspended (basal 2).
At the beginning of the study, plasma triglyceride values
were higher and HDL-cholesterol slightly lower than
those values generally accepted for health controls, while
total cholesterol and LDL-cholesterol were found to be
within the normal range. Along pyridoxine administra-
tion, triglyceride levels as well as total cholesterol and
HDL-cholesterol were significantly decreased. LDL-cho-
lesterol showed an increase that became significant after 2
months of treatment. After the suspension of the treat-
ment triglyceride, cholesterol and lipoprotein levels were
found to be similar to those obtained at the beginning of
the study.
Table 1: Plasma biochemical parameters of chronic renal failure patients treated with pyridoxine
Days of treatment
Basal 1 30 60 Basal 2
Total homocysteine (µmoles/l) 33.2 ± 4.3a 22.0 ± 1.5b 18.3 ± 1.5b 32.5 ± 2.2a
Triglyceride (mg/dl) 166.5 ± 5.8a 117.0 ± 6.3b 109.0 ± 6.5b 160.0 ± 6.0a
Total cholesterol (mg/dl) 186.3 ± 3.8a 170.9 ± 3.7b 177.4 ± 5.2b 188.5 ± 4.2a
HDL-cholesterol (mg/dl) 37.2 ± 1.2a 30.2 ± 0.8b 33.5 ± 1.1c 33.5 ± 0.9a
LDL cholesterol (mg/dl) 115.0 ± 2.0ab 120.8 ± 3.5bc 124.2 ± 2.2c 113.1 ± 2.2a
Data are the mean ± SEM. Values not bearing the same superscript letter are significantly different at P < 0.05.Page 2 of 6
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in basal samples presented changes in the fatty acid pat-
tern, indicating a mild fatty acid deficiency, frequently
observed in chronic renal failure. Thus, saturated acids
were increased whereas polyunsaturated acids were below
those values reported in health controls [6,25–28]. Pyri-
doxine administration did not ameliorate this pattern
which remained without changes all over the treatment,
even after withdrawal (results not shown).
The fatty acid composition of red blood cell membranes
is shown in Table 2. The patterns obtained in basal 1 and
2 samples were not different from those obtained from
normal subjects [6]. After pyridoxine treatment, a signifi-
cant increase in palmitoleic and stearic acids as well as a
decrease in palmitic acid were observed. No changes were
found in polyunsaturated fatty acids belonging to either
linoleic or α-linolenic family when compared to the basal
1. Four months after the end of treatment, the pattern
showed an enhancement in palmitic, palmitoleic and
oleic acids while 20:4 n-6 and 22:4 n-6 acids decreased.
Docosapentenoic as well as docosahexenoic acids from n-
3 series also diminished significantly.
The amount of different neutral and polar lipids as well as
the steady-state fluorescence anysotropy of DPH in eryth-
rocyte membranes, are shown in Table 3. At the beginning
of the study, the amount of cholesterol represented about
50% to that of phospholipids. When the patients were
treated with pyridoxine, a significant decrease in phos-
pholipids together with an increase in the cholesterol was
observed. In consequence, the relationship between cho-
lesterol and phospholipids was markedly incremented. A
significant increase in triglyceride and free fatty acids was
also observed in red blood cell membranes of treated
patients. Patients receiving pyridoxine supplementation
for 30 days, showed a significantly increased rotational
mobility of DPH. These values were further incremented
during the therapeutic treatment, remaining even high
after withdrawal.
Discussion
The present results indicated that the intravenous admin-
istration of high doses of vitamin B6 was effective in cor-
recting the hyperhomocysteinemia in the HD patients.
However, the homocysteine-lowering effect was mild
(55.1%) compared with that of folic acid observed in the
same population (31.9%) [17].
The hypertriglyceridemia is the most common plasma
lipid abnormality in patients with renal failure, and it has
been considered as a risk factor for atherosclerotic vascu-
lar disease [2,3]. Triglyceride levels are associated with an
increased risk factor even if they are within the range gen-
erally considered to be without clinical significance [3].
The reduction of plasma triglyceride levels observed after
vitamin B6 treatment indicated an amelioration of this
lipid abnormality. In the patients studied total plasma
cholesterol levels were within normal values and pyridox-
ine supplementation had a mild but significant choles-
terol-lowering effect (91.3%). Similar observations were
reported by Arnadottir et al. when vitamin B6 was orally
administered [20]. Contrasting to the reduction of these
biochemical results, we showed that HDL-cholesterol
decreased and LDL-cholesterol increased after 1 and 2
months of pyridoxine administration. Correspondingly,
plasma total cholesterol/HDL-cholesterol as well as LDL-
cholesterol/HDL-cholesterol ratios increased during the
treatment. This implies an undesirable effect since a risk of
coronary disease was attributed primarily to a reduction
in total cholesterol/HDL-cholesterol [29].
Another important factor in coronary heart disease is the
level of PUFA [30,31]. Fatty acid abnormalities have been
found in patients with different types of atherosclerosis
[32] and myocardial infarction [33]. The fatty acid pattern
observed in chronic renal failure patients is indicative of
an essential fatty acid deficiency. Polyunsaturated fatty
acids decreased whereas saturated fatty acids increased in
plasma and red blood cell membranes, altering the fluid-
ity in the latter [6,25–28]. During pyridoxine administra-
tion the pattern of either plasma or erythrocytes
polyunsaturated fatty acids remained invariable. The
decrease observed in arachidonic, 22:4 n-6 and 22:5 n-3
acids in red cell membranes after withdrawal was attrib-
uted to the gradual deterioration of the fatty acid pattern
observed in these patients [6].
Table 2: Effect of pyridoxine on the fatty acid composition in 
erythrocyte membranes
Days of treatment
Fatty acid Basal 1 30 60 Basal 2
16:0 22.0 ± 1.0a 19.0 ± 1.3a 17.0 ± 1.4b 23.8 ± 0.9a
16:1 0.3 ± 0.05a 1.0 ± 0.2b 1.0 ± 0.1b 1.3 ± 0.2b
18:0 20.4 ± 0.3a 22.0 ± 0.5b 23.0 ± 0.4b 19.3 ± 0.2c
18:1 14.7 ± 0.4 14.3 ± 0.5 14.7 ± 1.3 14.2 ± 0.6
18:2 n-6 10.7 ± 0.4 11.0 ± 0.5 10.5 ± 1.0 10.6 ± 0.5
20:3 n-6 1.9 ± 0.1 1.6 ± 0.1 2.1 ± 0.2 1.6 ± 0.1
20:4 n-6 19.4 ± 0.9a 19.0 ± 0.7a 20.6 ± 0.7a 15.7 ± 0.7b
22:4 n-6 0.5 ± 0.1a 0.4 ± 0.05a 0.5 ± 0.1a 0.2 ± 0.02b
22:5 n-6 4.7 ± 0.5 4.1 ± 0.3 4.7 ± 0.3 3.5 ± 0.2
22:5 n-3 2.6 ± 0.2a 2.3 ± 0.2ab 2.6 ± 0.2a 1.9 ± 0.1b
22:6 n-3 4.7 ± 0.3 5.6 ± 0.5 5.0 ± 0.5 4.2 ± 0.3
Results are the means of 12 determinations ± 1 SEM expressed as µg 
% of total fatty acids. Fatty acids are identified by: number of carbon 
atoms in the chain is given first, value following the colon represents 
number of double bonds (zero means saturated fatty acid); number 
following n- indicates the position of the last double bond counting 
the double bond from the terminal methyl group. Values not bearing 
the same superscript letter are significantly different at P < 0.05.Page 3 of 6
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increased and phospholipids decreased significantly, in
the red cell membranes after pyridoxine treatment. The
structural order of lipids in membranes is inversely related
to the molar cholesterol/phospholipid ratio [34], and it is
essentially determined by cholesterol content and the
degree of saturation of the phospholipid acyl chains [35].
We consider that the enhancement of cholesterol/phos-
pholipid ratio obtained from erythrocyte membranes was
the main caused for the decline of fluidity in the bilayer,
since polyunsaturated fatty acids remained invariable,
and the enhancement of free fatty acids of total lipids rep-
resented only 1–3% of the bilayer components.
Comparing the biochemical profiles obtained after the
administration of pyridoxine to those reported when the
same patients were treated with folic acid [17], we con-
clude that vitamin-B6 was highly effective in decreasing
triglyceride levels in spite of a mild depression produced
in total homocysteine levels. Moreover, pyridoxine pro-
duced a moderate increment (5%) in LDL-cholesterol ver-
sus the enhancement observed after folic acid
administration (35%). The lipid pattern of erythrocyte
membranes was similar in the samples obtained from the
patients under either pyridoxine or folic acid treatment.
Conclusions
Based on these results, we consider that i.v. pyridoxine
therapy appears to be an effective and appropriate strategy
to ameliorate plasma homocysteine, triglycerides and
total cholesterol levels in patients with chronic renal fail-
ure, who are reliably known to be at high risk of athero-
sclerosis. However, it was insufficient to restore
polyunsaturated fatty acid pattern and erythrocyte lipid
profile. Regarding that it was evident that correction of
hyperhomocysteinemia with folic acid in patients on dial-
ysis, produced an increase in the serum concentration of
unsaturated fatty acids [17], we considered that further
research using vitamin B6 for a long period of time would
be necessary in an attempt to restore the fatty acid pattern
and to improve the rigidity of the red cell membranes.
Subjects and methods
Patients
Twelve uremic patients (both sexes: 5 men, 7 women,
aged 47.9 ± 15.5) undergoing maintenance hemodialysis
were studied. The underlying renal diseases were adult
polycystic kidney disease (2 cases); hypertensive nephro-
sclerosis (3 cases); obstructive uropathy (3 cases) and
unknown diagnosis (4 cases). Their biochemical and
dialysis situation (mean ± standard deviation) before the
study were: body mass index 21.6 ± 3.1; dialysis time 41 ±
31.7 months; serum creatinine 8.4 ± 3.3 mg %; hemat-
ocrit 33.2 ± 5.8%; ktv 1.38 ± 0.37; intraerythrocytic folic
acid 1177.3 ± 187.8 ng/ml; serum B12 vitamin 489.2 ±
270.5 pg/ml; serum albumin 4.07 ± 0.35 g %. To prevent
folate and pyridoxine deficiency, all patients received an
intravenous (i.v.) supplementation of folic acid (10 mg)
and pyridoxine (300 mg) postdialysis, for three months
before starting this study. Dialysis was carried out with
bicarbonate dialysate, volumetric machines (Gambro
AK90), and polysulphone capillary filters 1.8 m2 low flux
(Fresenius F8). At the end of each session, all patients
received an i.v. supplementation of 300 mg pyridoxine
three times a week for 60 days. Samples were taken at the
fasting state (12 h) and immediately before the hemodial-
ysis session at the beginning of the study (basal 1), after
30 and 60 days of treatment, and four months after with-
drawal (basal 2). The study was approved by the HIGA
San Martín hospital's ethical committee.
Isolation of erythrocyte membranes
Blood was collected in test tubes containing an anticoag-
ulant ethylenediaminetetraacetic acid (EDTA) solution
(Wiener Lab., Rosario, Argentina). Whole blood was cen-
trifuged, the plasma was immediately separated, and the
packed red blood cells were washed four times at 4°C
with buffered solution containing NaCl (140 mM), KCl (5
mM), NaHSO4 (1 mM) and Tris buffer (10 mM, pH 7.4).
After agitation they were kept at 4°C for 10 min, and cen-
trifuged at 16,000 g for 15 min. This procedure was done
twice, leaving a substantially hemoglobin-free pellet of
erythrocyte membranes, which was resuspended in a
Table 3: Pyridoxine effect on the lipid composition (mol %) and fluorescence anisotropy (rs) of DPH in erythrocyte membranes
Days of treatment
Basal 1 30 60 Basal 2
Phospholipids 65.8 ± 0.9a 57.3 ± 0.5b 57.8 ± 0.8b 58.0 ± 1.3b
Cholesterol 33.2 ± 0.9a 38.2 ± 0.6b 37.5 ± 0.8b 39.1 ± 1.3b
Triglyceride 0.4 ± 0.03a 2.0 ± 0.1b 2.1 ± 0.1b 1.0 ± 0.2c
Free fatty acids 0.6 ± 0.01a 2.5 ± 0.1b 2.6 ± 0.1b 1.9 ± 0.2c
Cholesterol/phospholipids 0.50 0.67 0.65 0.67
rs 0.235 ± 0.001a 0.249 ± 0.002b 0.249 ± 0.002b 0.253 ± 0.002a
Data are the mean ± SEM. Values not bearing the same superscript letter are significantly different at P < 0.05.Page 4 of 6
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assayed.
Chemical determinations
Plasma cholesterol and triglycerides were determined
using commercially-available enzymatic methods
(Wiener Lab., Rosario, Argentina). High-density-lipopro-
tein (HDL) cholesterol was also analyzed enzymatically
after precipitation of very-low-density and low-density
lipoproteins (LDL) with magnesium-dextran (Wiener
Lab., Rosario, Argentina). Plasma total homocysteine con-
centration was determined using an enzyme immu-
noassay method (Axis Biochemical, Oslo, Norway).
Lipid extraction and analysis
Lipids from plasma and erythrocyte membranes were
extracted with chloroform-methanol (2:1 v/v). An aliquot
from the organic phase was methylated and analyzed
using a Hewlett-Packard Model 5840-A gas-liquid chro-
matograph equipped with a flame-ionization detector.
Another aliquot from the organic phase was separated to
determine phospholipid and neutral lipid content
through a flame ionization detector (FID) of an Iatroscan
apparatus model TH 10. Lipids were separated on previ-
ously activated chromarods type S-III under a double-
development system. The first mobile phase was hexane-
benzene (70:30 v/v) whereas the second one was ben-
zene-chloroform-formic acid (70:25:2 v/v/v). Lipid spe-
cies were quantified by comparison with known amounts
of pure standards run under the same conditions. The sig-
nals from the FID were registered on a Hewlett-Packard
model HP-3396 A integrator.
Fluorescence anisotropy measurements
Steady-state fluorescence anisotropy (rs) was measured in
erythrocyte membranes in a SLM 4800 C spectrofluorom-
eter as previously described by Garda et al. [36]. The probe
used was 1,6-diphenyl-1,3,5 hexatriene (DPH). Excitation
wavelength was 360 nm and the emitted light was passed
through a sharp cut-off filter (Schott KV 389). Light scat-
tering of blanks represented less than 5% and fluorescence
values were corrected accordingly. The phospholi-
pid:probe ratio was maintained at more than 200:1
(mol:mol) in order to minimize possible probe-probe
interactions.
Statistical analyses
Results were tested statistically using either the Student t-
test compared to the respective control or the one-way
analyses of variance (ANOVA) as appropriate.
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